{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:43:03Z","timestamp":1793727783882,"version":"4.6.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002409"],"award-info":[{"award-number":["82002409"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872449"],"award-info":[{"award-number":["81872449"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073396"],"award-info":[{"award-number":["82073396"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2020A1515010020"],"award-info":[{"award-number":["2020A1515010020"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2018A0303130243"],"award-info":[{"award-number":["2018A0303130243"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1), with a shorter elimination half-life (t\n                      <jats:sub>1\/2<\/jats:sub>\n                      ) for CTLA-4. We report results from a phase I\/Ib study of QL1706 in patients with advanced solid tumors who failed standard therapies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the phase I study, QL1706 was administered intravenously once every 3\u00a0weeks at one of five doses ranging from 0.3 to 10\u00a0mg\/kg, and the maximum tolerated dose, recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of QL1706 were investigated. In the phase Ib study, QL1706 was administered at the RP2D intravenously every 3\u00a0weeks, and the preliminary efficacies in non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma (NPC), cervical cancer (CC), and other solid tumors were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between March 2020 and July 2021, 518 patients with advanced solid tumors were enrolled (phase I,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200999; phase Ib,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009419). For all patients, the three most common treatment-related adverse events (TRAEs) were rash (19.7%), hypothyroidism (13.5%), and\u00a0pruritus (13.3%). The TRAEs and immune-related adverse events (irAEs) of grade\u2009\u2265\u20093 occurred in 16.0% and 8.1% of patients, respectively. In phase I, 2 of 6 patients in the 10mg\/kg group experienced dose-limiting toxicities (DLTs) (grade 3 thrombocytopenia and grade 4 immune-mediated nephritis), so the maximum tolerated dose (MTD) was reached at 10\u00a0mg\/kg. The RP2D was determined to be 5\u00a0mg\/kg based on comprehensive analysis of tolerability, PK\/PD, and efficacy. For all patients who received QL1706 at the RP2D, the objective response rate (ORR) and median duration of response were 16.9% (79\/468) and 11.7\u00a0months (8.3\u2014not reached [NR]), respectively; and the ORRs were 14.0% (17\/121) in NSCLC, 24.5% (27\/110) in NPC, 27.3% (15\/55) in CC, 7.4% (2\/27) in colorectal cancer, 23.1% (6\/26) in small cell lung cancer. For immunotherapy-naive patients, QL1706 exhibited promising antitumor activities, especially in NSCLC, NPC, and CC, with ORRs of 24.2%, 38.7%, and 28.3%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>QL1706 was well tolerated and demonstrated promising antitumor activity in solid tumors, especially in NSCLC, NPC, and CC patients. It is currently being evaluated in randomized phase II (NCT05576272, NCT05179317) and phase III (NCT05446883, NCT05487391) trials.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial Registration<\/jats:italic>\n                      ClinicalTrials.gov Identifier: NCT04296994 and NCT05171790.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-023-01445-1","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T09:04:45Z","timestamp":1683536685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["First-in-human phase I\/Ib study of QL1706 (PSB205), a bifunctional PD1\/CTLA4 dual blocker, in patients with advanced solid tumors"],"prefix":"10.1186","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04296994","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05171790","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yuanyuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangcai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanben","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenhong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weineng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Fanslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"1445_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","volume":"38","author":"A Rotte","year":"2019","unstructured":"Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38:255.","journal-title":"J Exp Clin Cancer Res"},{"key":"1445_CR2","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.3390\/ijms21124427","volume":"21","author":"O Kooshkaki","year":"2020","unstructured":"Kooshkaki O, Derakhshani A, Hosseinkhani N, Torabi M, Safaei S, Brunetti O, et al. Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials. Int J Mol Sci. 2020;21:4427.","journal-title":"Int J Mol Sci"},{"key":"1445_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","volume":"22","author":"I Pires da Silva","year":"2021","unstructured":"Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22:836\u201347.","journal-title":"Lancet Oncol"},{"key":"1445_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28.","journal-title":"Mol Cancer"},{"key":"1445_CR5","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346.","journal-title":"N Engl J Med"},{"key":"1445_CR6","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020\u201331.","journal-title":"N Engl J Med"},{"key":"1445_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","volume":"6","author":"NA Rizvi","year":"2020","unstructured":"Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020;6:661\u201374.","journal-title":"JAMA Oncol"},{"key":"1445_CR8","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6:e204564.","journal-title":"JAMA Oncol"},{"key":"1445_CR9","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","volume":"35","author":"M Sznol","year":"2017","unstructured":"Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;35:3815\u201322.","journal-title":"J Clin Oncol"},{"key":"1445_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.18.01998","volume":"37","author":"C Lebb\u00e9","year":"2019","unstructured":"Lebb\u00e9 C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 trial. J Clin Oncol. 2019;37:867\u201375.","journal-title":"J Clin Oncol"},{"key":"1445_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","volume":"18","author":"MD Hellmann","year":"2017","unstructured":"Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18:31\u201341.","journal-title":"Lancet Oncol"},{"key":"1445_CR12","doi-asserted-by":"crossref","unstructured":"Perets R, Bar J, Rasco DW, Ahn MJ, Yoh K, Kim DW, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2020.","DOI":"10.1016\/j.annonc.2020.11.020"},{"key":"1445_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.annonc.2020.11.020","volume":"32","author":"R Perets","year":"2021","unstructured":"Perets R, Bar J, Rasco DW, Ahn MJ, Yoh K, Kim DW, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021;32:395\u2013403.","journal-title":"Ann Oncol"},{"key":"1445_CR14","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/S0090-8258(22)01293-8","volume":"166","author":"X Wu","year":"2022","unstructured":"Wu X, Ji J, Lou H, Li Y, Feng M, Xu N, et al. Efficacy and safety of cadonilimab, an anti-PD-1\/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R\/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075). Gynecol Oncol. 2022;166:S47\u20138.","journal-title":"Gynecol Oncol"},{"key":"1445_CR15","unstructured":"https:\/\/patft.uspto.gov\/netacgi\/nph-Parser?Sect1=PTO1&Sect2=HITOFF&p=1&u=\/netahtml\/PTO\/srchnum.html&r=1&f=G&l=50&d=PALL&s1=11124570.PN Accessed 17 Sept 2022."},{"key":"1445_CR16","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"1445_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202102500","volume":"8","author":"C Jiang","year":"2021","unstructured":"Jiang C, Zhang L, Xu X, Qi M, Zhang J, He S, et al. Engineering a smart agent for enhanced immunotherapy effect by simultaneously blocking PD-L1 and CTLA-4. Adv Sci (Weinh). 2021;8: e2102500.","journal-title":"Adv Sci (Weinh)"},{"key":"1445_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","volume":"20","author":"T Zhang","year":"2023","unstructured":"Zhang T, Lin Y, Gao Q. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy. Cancer Biol Med. 2023;20:181\u201395.","journal-title":"Cancer Biol Med"},{"key":"1445_CR19","doi-asserted-by":"publisher","first-page":"2180794","DOI":"10.1080\/19420862.2023.2180794","volume":"15","author":"X Pang","year":"2023","unstructured":"Pang X, Huang Z, Zhong T, Zhang P, Wang ZM, Xia M, et al. Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. MAbs. 2023;15:2180794.","journal-title":"MAbs"},{"key":"1445_CR20","doi-asserted-by":"publisher","first-page":"254ra128","DOI":"10.1126\/scitranslmed.3008918","volume":"6","author":"P Kvistborg","year":"2014","unstructured":"Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6:254ra128.","journal-title":"Sci Transl Med"},{"key":"1445_CR21","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","volume":"77","author":"DY Oh","year":"2017","unstructured":"Oh DY, Cham J, Zhang L, Fong G, Kwek SS, Klinger M, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 2017;77:1322\u201330.","journal-title":"Cancer Res"},{"key":"1445_CR22","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1517\/14712598.7.8.1245","volume":"7","author":"LF Langer","year":"2007","unstructured":"Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther. 2007;7:1245\u201356.","journal-title":"Expert Opin Biol Ther"},{"key":"1445_CR23","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3389\/fphar.2019.01300","volume":"10","author":"H Xu","year":"2019","unstructured":"Xu H, Tan P, Ai J, Zhang S, Zheng X, Liao X, et al. Antitumor activity and treatment-related toxicity associated with nivolumab plus ipilimumab in advanced malignancies: a systematic review and meta-analysis. Front Pharmacol. 2019;10:1300.","journal-title":"Front Pharmacol"},{"key":"1445_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.2020.38.4_suppl.11","volume":"38","author":"H-J Lenz","year":"2020","unstructured":"Lenz H-J, Lonardi S, Zagonel V, Van Cutsem E, Limon ML, Wong KYM, et al. Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high\/DNA mismatch repair deficient metastatic colorectal cancer: clinical update. J Clin Oncol. 2020;38:11.","journal-title":"J Clin Oncol"},{"key":"1445_CR25","doi-asserted-by":"crossref","unstructured":"Baas P, Scherpereel A, Nowak A, Fujimoto N, Zalcman GJJoTO. ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743. 2020;15:e42.","DOI":"10.1016\/j.jtho.2020.08.004"},{"key":"1445_CR26","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277\u201390.","journal-title":"N Engl J Med"},{"key":"1445_CR27","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480\u201392.","journal-title":"Lancet Oncol"},{"key":"1445_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122\u201333.","journal-title":"N Engl J Med"},{"key":"1445_CR29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21:509\u201328.","journal-title":"Nat Rev Drug Discov"},{"key":"1445_CR30","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","volume":"36","author":"BBY Ma","year":"2018","unstructured":"Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol. 2018;36:1412\u20138.","journal-title":"J Clin Oncol"},{"key":"1445_CR31","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35:4050\u20136.","journal-title":"J Clin Oncol"},{"key":"1445_CR32","doi-asserted-by":"crossref","unstructured":"Yang Y, Zhou T, Chen X, Li J, Pan J, He X, et al. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study). J Immunother Cancer. 2021;9.","DOI":"10.1136\/jitc-2021-003790"},{"key":"1445_CR33","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"FH Wang","year":"2021","unstructured":"Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol. 2021;39:704\u201312.","journal-title":"J Clin Oncol"},{"key":"1445_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/sj.bjc.6603580","volume":"96","author":"KM Lau","year":"2007","unstructured":"Lau KM, Cheng SH, Lo KW, Lee SA, Woo JK, van Hasselt CA, et al. Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer. 2007;96:617\u201322.","journal-title":"Br J Cancer"},{"key":"1445_CR35","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","volume":"37","author":"HC Chung","year":"2019","unstructured":"Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37:1470\u20138.","journal-title":"J Clin Oncol"},{"key":"1445_CR36","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ygyno.2021.08.018","volume":"163","author":"DM O'Malley","year":"2021","unstructured":"O\u2019Malley DM, Oaknin A, Monk BJ, Selle F, Rojas C, Gladieff L, et al. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and\/or metastatic cervical cancer. Gynecol Oncol. 2021;163:274\u201380.","journal-title":"Gynecol Oncol"},{"key":"1445_CR37","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1200\/JCO.21.02067","volume":"40","author":"DM O'Malley","year":"2022","unstructured":"O\u2019Malley DM, Neffa M, Monk BJ, Melkadze T, Huang M, Kryzhanivska A, et al. Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study. J Clin Oncol. 2022;40:762\u201371.","journal-title":"J Clin Oncol"},{"key":"1445_CR38","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","volume":"15","author":"HC Chung","year":"2020","unstructured":"Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15:618\u201327.","journal-title":"J Thorac Oncol"},{"key":"1445_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","volume":"14","author":"N Ready","year":"2019","unstructured":"Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019;14:237\u201344.","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01445-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01445-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01445-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T09:11:05Z","timestamp":1683537065000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01445-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01445-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"27 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and all amendments were approved by the Institutional Review Boards of all participating institutions. All participants provided written informed consent. The study was done in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Li Zhang reports receiving research support from Jiangsu Hengrui Pharmaceuticals, Eli Lilly, Novartis, Roche, and Bristol-Myers Squibb. Zhi Liu, Yufeng Peng, Bill Fanslow, Xian Huang, and Wei Yan are employees of Sound Biologics. Xiaoyan Kang, Shilin Xue, Guihong Yang, and Yingying Yang are employees of Qilu Pharma Ltd. All other authors declare no potential competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}